The effect of SOC + AAP was also observed to be similar in both low‐risk and high‐risk metastatic disease risk groups for the secondary outcomes of failure‐free survival, progression‐free survival, metastatic progression‐free survival, skeletal‐related events and disease‐specific survival. This evidence concerns the gene UBXN11 and metastatic neoplasm.